Form 8-K - Current report:
SEC Accession No. 0001193125-24-036588
Filing Date
2024-02-14
Accepted
2024-02-14 17:15:18
Documents
14
Period of Report
2024-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d769501d8k.htm   iXBRL 8-K 27997
  Complete submission text file 0001193125-24-036588.txt   154085

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA implq-20240212.xsd EX-101.SCH 2499
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE implq-20240212_lab.xml EX-101.LAB 18699
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE implq-20240212_pre.xml EX-101.PRE 11675
16 EXTRACTED XBRL INSTANCE DOCUMENT d769501d8k_htm.xml XML 3901
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

EIN.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 24640535
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)